Multi-arm clinical trials with treatment selection: what can be gained and at what price?
Multi-arm clinical trials with treatment selection: what can be gained and at what price?
With current success rates of confirmatory studies being only around 50%, new approaches to drug development are paramount.Many trials fail simply because ineffective treatments are identified too late.In this paper, we discuss the utility of multi-arm studies with treatment selection as a potential strategy that can reduce the high attrition …